NCT03236259 is a NA clinical trial of Brainport high dose in Cognitive Impairment, sponsored by Maastricht University Medical Center.

Who is sponsoring NCT03236259?

NCT03236259 is sponsored by Maastricht University Medical Center.

What drugs are being tested in NCT03236259?

Interventions in NCT03236259: Brainport high dose, Brainport low dose, Placebo.

What condition does NCT03236259 study?

NCT03236259 studies Cognitive Impairment, Overweight and Obesity.

Is NCT03236259 still recruiting?

NCT03236259 is currently completed. Last updated 25 February 2021.

Last reviewed 2021-02-25 · How we verify

NCT03236259

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Berry Extract Administration on Cognitive Health

Completed NA Last updated 25 February 2021

What this trial tests

NA trial testing Brainport high dose in Cognitive Impairment in 102 participants. Completed in 21 August 2018.

Timeline

21 February 2017

Primary endpoint
21 August 2018

21 August 2018

Quick facts

Lead sponsor	Maastricht University Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	102
Start date	21 February 2017
Primary completion	21 August 2018
Estimated completion	21 August 2018
Sites	1 location across Netherlands

Drugs / interventions tested

Brainport high dose
Brainport low dose
Placebo

Conditions studied

Cognitive Impairment — all drugs for Cognitive Impairment →
Overweight and Obesity — all drugs for Overweight and Obesity →

Sponsor

Maastricht University Medical Center

Who can join

Adults 40 to 60, any sex, with Cognitive Impairment or Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effects of daily supplementation of Brainport for a period of 6 months on cognitive health.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Effect of Long-Term <i>Aronia</i> <i>melanocarpa</i> Extract Supplementation on Cognitive Performance, Mood, and Vascular Function: A Randomized Controlled Trial in Healthy, Middle-Aged Individuals.
Ahles S, Stevens YR, Joris PJ, Vauzour D, et al · · 2020 · cited 30× · PMID 32824483 · DOI 10.3390/nu12082475

Verify or expand the search:

Other recruiting trials for Cognitive Impairment

Currently open trials in the same condition.

NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting

Other Maastricht University Medical Center trials

Trials by the same sponsor.

NCT04603261 — Time to Excretion of Contrast, a Maastricht Prospective Observational Study · withdrawn
NCT04598516 — Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30 · withdrawn
NCT04597892 — Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast · withdrawn
NCT07287358 — Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II · NA · not yet recruiting
NCT07501780 — Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03236259 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maastricht University Medical Center
Last refreshed: 25 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03236259.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing